27. Treatment result of neoadjuvant therapy with dose-dense AC-T regimen in combination with anti-HER2 therapy in HER2-positive breast cancer in Hanoi Medical University Hospital
Main Article Content
Abstract
A retrospective descriptive study with longitudinal follow-up aimed at evaluating the efficacy of neoadjuvant treatment with dose-dense AC-T chemotherapy in combination with anti-HER2 agents (trastuzumab, pertuzumab) in HER2-positive breast cancer patients at the Department of Oncology and Palliative care, Hanoi Medical University Hospital from January 2016 to September 2023. The results showed that: in 37 patients enrolled in the study, median age was 50.2 (range 33 - 74 years old), 24 (64.9%) were at stage II and 13 (35.1%) were at stage III. Median tumor size was 40mm, and the rate of patients who had hormone receptor (HR) positive diseases was 62.2%. Total pathological complete response (tpCR) was achieved in 54.1% of the evaluated patients. Patients with HR negative had a statistically significant higher response rate (p < 0.05), while there was no significant association between tpCR rates and age, tumor size, tumor grade, Ki-67 expression, and regimen. There was no patient who had progressive disease.
Article Details
Keywords
HER2-positive breast cancer, neoadjuvant therapy, dose-dense AC-T, anti-HER2 therapy
References
2. Chumsri S, Li Z, Serie DJ, et al. Incidence of Late Relapses in Patients With HER2- Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol. 2019;37(35):3425-3435. doi:10.1200/JCO.19.00443
3. Davide Mauri, Nicholas Pavlidis, John P A. IoannidisNeoadjuvant versus adjuvant systemic treatment in breast cancer: A meta- analysis. J Natl Cancer Inst. 2005;97(3):188- 94. doi:10.1093/jnci/dji021
4. Ellie Vershvovsky. NOAH Trial Shows Survival Benefit With Neoadjuvant Trastuzumab – Hematology & Oncology. Clinical Advances in Hematology & Oncology. 2010;8(2). Accessed February 14, 2023. https:// www.hematologyandoncology.net/archives/february-2010/noah-trial-shows-survival- benefit-with-neoadjuvant-trastuzumab/
5. Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27-35. doi:10.1016/j.ejca.2017.10.021
6. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470- 2045(11)70336-9
7. Phung HT, Nguyen HT, Nguyen TV, et al. Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam. Breast Cancer (Dove Med Press). 2020;12:117-122. doi:10.2147/BCTT.S268369
8. Phùng Thị Huyền. Kết quả điều trị bổ trợ trước phác đồ hóa chất kết hợp trastuzumab và pertuzumab trên ung thư vú có HER2- NEU dương tính. Tạp chí Y học Việt Nam. 2022;509(1). Published December 1, 2022. https://tapchiyhocvietnam.vn/index.php/vmj/ article/view/1761
9. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351-3357. doi:10.1200/ JCO.2010.31.4930
10. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024-2031. doi:10.1200/JCO.2009.23.8451